{"entity":{"id":"steap1","kind":"target","name":"STEAP1","aka":[],"tldr":"STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.","summary":"Six-transmembrane epithelial antigen of the prostate 1 is expressed in most prostate cancers including PSMA-low and neuroendocrine-like disease, with limited normal expression. Xaluritamig (STEAP1×CD3 XmAb 2+1) produced PSA50 in ~half of heavily pretreated mCRPC patients at target doses in phase 1 and is in two phase 3 trials (XALute post-taxane; XALience with abiraterone chemo-naive). Also an ADC target historically (vandortuzumab vedotin, discontinued).","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/STEAP1","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/STEAP1"}],"tags":["t-cell-engager-target"],"related":[],"indications":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: no peer-reviewed STEAP1 expression series with a stated denominator was found for prostate cancer; the widely repeated '>80%' figure could not be traced to a series with an n, so it has been removed."],"symbol":"STEAP1","hgnc":"HGNC:11378","ensembl":"ENSG00000164647","uniprot":"Q9UHE8","entrez":"26872","biology":"STEAP1 is a metalloreductase at cell junctions, upregulated by androgen receptor signalling; its expression is partly independent of PSMA, making it complementary.","whereFound":["Prostate cancer (most cases)","Ewing sarcoma","Bladder (subset)"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/steap1/","neighbours":{"indication":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}]}}